Evaluation of the STAT3 inhibitor GLG-302 for the prevention of estrogen receptor-positive and -negative mammary cancers

por Shoemaker, Robert H., Fox, Jennifer T., Juliana, M. Margaret, Moeinpour, Fariba L., Grubbs, Clinton J.
Publicado en Oncol Rep (2019)

Combination of erlotinib and naproxen employing pulsatile or intermittent dosing profoundly inhibits urinary bladder cancers

por Mohammed, Altaf, Miller, Mark Steven, Lubet, Ronald A., Suen, Chen S., Sei, Shizuko, Shoemaker, Robert H., Juliana, Margaret M., Moeinpour, Fariba L, Grubbs, Clinton J.
Publicado en Cancer Prev Res (Phila) (2019)

Methyl-Substituted Conformationally Constrained Rexinoid Agonists for the Retinoid X Receptors Demonstrate Improved Efficacy for Cancer Therapy and Prevention

por Desphande, Anil, Xia, Gang, Boerma, LeeAnn J., Vines, Kimberly K, Atigadda, Venkatram R., Lobo-Ruppert, Susan, Grubbs, Clinton J., Moeinpour, Fariba L, Smith, Craig D., Christov, Konstantin, Brouillette, Wayne J., Muccio, Donald D.
Publicado en Bioorg Med Chem (2013)